BACKGROUND: Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute myeloid leukemia (AML) is an immnunophenotypically heterogeneous group of diseases, with CD34(+) cases being associated with drug resistance and poor outcome. We investigated the effects of bortezomib on the growth and survival of AML cells. DESIGN AND METHODS: We studied the in vitro activity and mechanism of action of bortezomib on both cell lines and fresh cells from 28 AML patients including CD34(+) and CD34(-) cases. RESULTS: Bortezomib showed potent anti-AML activity (IC(50) < 50 nM), which was greater than that of conventional agents (doxorubicin, cytarabine and fludarabine). Moreover, synergistic effects were observed when bortezomib was administered in combination with doxorubicin and cytarabine. Mechanistically, bortezomib induced accumulation of cells in the G(2)/M phase, with up-regulation of p27, together with cell death through an increase in the mitochondrial outer membrane permeability involving caspase-dependent and -independent pathways. The apoptotic activity of bortezomib on fresh CD34(+) blast cells from patients was similar to that observed on CD34(-)blast cells. Importantly, bortezomib was significantly more active than doxorubicin in the immature CD34(+) cells, while there were no differences in its action on CD34(-) cells. CONCLUSIONS: Bortezomib induces apoptosis in acute myeloid leukemia cells in vitro. Whether this drug might be useful in the treatment of patients with acute myeloid leukemia can be established only in ad hoc clinical trials.
BACKGROUND: Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute myeloid leukemia (AML) is an immnunophenotypically heterogeneous group of diseases, with CD34(+) cases being associated with drug resistance and poor outcome. We investigated the effects of bortezomib on the growth and survival of AML cells. DESIGN AND METHODS: We studied the in vitro activity and mechanism of action of bortezomib on both cell lines and fresh cells from 28 AMLpatients including CD34(+) and CD34(-) cases. RESULTS:Bortezomib showed potent anti-AML activity (IC(50) < 50 nM), which was greater than that of conventional agents (doxorubicin, cytarabine and fludarabine). Moreover, synergistic effects were observed when bortezomib was administered in combination with doxorubicin and cytarabine. Mechanistically, bortezomib induced accumulation of cells in the G(2)/M phase, with up-regulation of p27, together with cell death through an increase in the mitochondrial outer membrane permeability involving caspase-dependent and -independent pathways. The apoptotic activity of bortezomib on fresh CD34(+) blast cells from patients was similar to that observed on CD34(-)blast cells. Importantly, bortezomib was significantly more active than doxorubicin in the immature CD34(+) cells, while there were no differences in its action on CD34(-) cells. CONCLUSIONS:Bortezomib induces apoptosis in acute myeloid leukemia cells in vitro. Whether this drug might be useful in the treatment of patients with acute myeloid leukemia can be established only in ad hoc clinical trials.
Authors: Enrique Colado; Teresa Paíno; Patricia Maiso; Enrique M Ocio; Xi Chen; Stela Alvarez-Fernández; Norma C Gutiérrez; Jesús Martín-Sánchez; Juan Flores-Montero; Laura San Segundo; Mercedes Garayoa; Diego Fernández-Lázaro; Maria-Belen Vidriales; Carlos M Galmarini; Pablo Avilés; Carmen Cuevas; Atanasio Pandiella; Jesús F San-Miguel Journal: Haematologica Date: 2011-02-17 Impact factor: 9.941
Authors: Kshama Gupta; Inna Kuznetsova; Olga Klimenkova; Maksim Klimiankou; Johann Meyer; Malcolm A S Moore; Cornelia Zeidler; Karl Welte; Julia Skokowa Journal: Blood Date: 2014-01-06 Impact factor: 22.113
Authors: M A Laussmann; E Passante; H Düssmann; J A Rauen; M L Würstle; M E Delgado; M Devocelle; J H M Prehn; M Rehm Journal: Cell Death Differ Date: 2011-04-01 Impact factor: 15.828
Authors: Liwen Wang; Sean W Harshman; Shujun Liu; Chen Ren; Hua Xu; Larry Sallans; Michael Grever; John C Byrd; Guido Marcucci; Michael A Freitas Journal: Proteomics Date: 2010-12 Impact factor: 3.984
Authors: Wanlong Ma; Hagop Kantarjian; Benjamin Bekele; Amber C Donahue; Xi Zhang; Zhong J Zhang; Susan O'Brien; Elihu Estey; Zeev Estrov; Jorge Cortes; Michael Keating; Francis Giles; Maher Albitar Journal: Clin Cancer Res Date: 2009-05-19 Impact factor: 12.531